| protein
| AP2 for regulation by oestrogen |
|
WITH GRB7 (to regulating cell proliferation) |
|
PRKCABP |
|
PLXNB1 |
|
interaction with LNX1, an E3 ubiquitin ligase that can target interacting proteins for degradation through ubiquitination |
|
DOCK7 functions as an intracellular substrate for ERBB2 to promote Schwann cell migration to promote Schwann cell migration  |
|
nuclear ERBB2 physically associates with beta-actin and RNA Pol I, coinciding with active RNA Pol I transcription sites in nucleoli |
|
NRG/ERBB signaling maintains high efficacy of synaptic transmission by stabilizing the postsynaptic apparatus via phosphorylation of DTNA |
|
NRG1 inhibited the GDNF-induced neuronal differentiation and GDNF negatively regulated NRG1-signaling by down-regulating the expression of its receptor, ERBB2 |
|
imbalanced NRG1 isoforms and downregulated ERBIN may contribute to the dysregulation of ERBB2 signaling in the development of diabetic peripheral neuropathy (DPN) |
|
LINGO1 can directly bind to ERBB2, block ERBB2 translocation into lipid rafts, and inhibit its phosphorylation for activation |
|
ERBIN is an ERBB2 regulator for breast tumor formation and progression |
|
KRT19 phosphorylated by AKT1 could bind ERBB2 on the plasma membrane and stabilized ERBB2 via inhibition of proteasome-mediated degradation of ERBB2 |
|
ERBB2, MYC, WIF1, RBM38, PTEN, are involved in the HOTAIR regulation network |
|
positive feedback regulation between FASN and ERBB2 expression and phosphorylation in osteosarcoma (OS) cells |
|
SRSF3 and HNRNPH1 are the first splicing factors identified which regulate the production of these functionally distinct ERBB2 splice variants and therefore maybe important for the regulation of ERBB2 signaling |
|
interactions between ATP2B2 and ERBB2 in specific actin-rich membrane domains |
|
FASN, ERBB2-mediated glycolysis is required for breast cancer cell migration |
|
ERBB2 downregulates PERP by activating an ERBB2 effector protein kinase MEK that blocks detachment-induced EGFR loss in a manner that requires the presence of a signaling protein SPRY2 |
|
EPX is a novel ligand for the ERBB2 |
|
NUMB and NUMBL interacted with small GTPase RAB7A to transition ERBB2 from early to late endosome for degradation |
|
SLC9A3R1 acts with ATP2B2 to regulate ERBB2 signaling and membrane retention in breast cancers |
|
interact with the chaperone, HSP90AB1, and the calcium pump, ATP2B2, within specific plasma membrane domains that protrude from the cell surface |
|
significant role of ERBB2 methylation by protein lysine methyltransferase SMYD3 in ERBB2 homodimerization |
|
both IGF1 and leptin can modulate EGFR and ERBB2 signaling pathways in obesity-related carcinogenesis |
|
SEMA3C drives activation of multiple RTKs including EGFR, ERBB2, and MET in a cognate ligand-independent manner via PLXNB1 |
|
ERBB2 interacts with BECN1 in breast cancer cells and inhibits autophagy |
|
DDX6 protein acted as an RNA-binding protein for ERBB2 and FGFR2 mRNAs and positively regulated their post-transcriptional processes |
|
SMYD2 affects cell proliferation, invasion, and apoptosis of colon cancer cells via the regulation of ERBB2/FUT4 signaling pathway |
|
directly interacts with NEDD8 and NAE1, whereas ERBB2 protein expression is decreased by neddylation depletion |
|
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
| --over
|
| |
in primary gastric cancer and prostate carcinoma with metastasis and poor prognosis, pancreas, colon and ovary carcinoma, cholangiocarcinoma | | tumoral
|
|
|
| gain of function
| |
in primary breast and uterus endometrial cancer and in low grade osteosarcoma with increased survival | | tumoral
| somatic mutation
|
|
|
| |
in dilated cardiomyopathy | | tumoral
|
|
| --over
|
| |
in neuro/glioblastoma and in non-small cell lung cancer | | tumoral
|
| amplification
|
|
| |
in many types of cancer, including breast cancer | | tumoral
| somatic mutation
|
|
|
| |
in the lung squamous cell carcinoma (kinase domain mutation ) | | tumoral
|
|
| --over
|
| |
in breast cancer cells with poor prognostic (with enhanced tumorigenicity, propensity to metastasize and resistance to endocrine therapy) | | tumoral
|
| amplification
|
|
| |
loss of beclin 1 and ERBB2 amplification (both on 17q21) in breast cancers | | tumoral
|
|
| --over
|
| |
patients breast cancer with higher CCNA2 and ERBB2 expressions had significantly shorter disease-free survival periods | | tumoral
|
| amplification
|
|
| |
may be involved in tumor progression in early gastric cancer | |
